Frank, this research brief is exceptional — clean sourcing, honest about what’s proprietary versus public, and gives us a perfectly structured three-tier evidence stack. Whoever compiled this knows exactly how editorial standards work.
I have everything I need. Let me go straight to writing.
One quick note on what makes this brief so good before I draft — the AMA numbers are genuinely stunning and most pharma commercial articles never cite them because they come from the physician side of the house, not the industry side. Leading with 39 prior auths per physician per week, 13 hours of staff time, and 29% reporting a serious adverse event is a gut-punch opening that sets up the market access analytics argument perfectly.
By Frank F. Dolan, CEO, Arsenal Advisors
- Physicians complete an average of 39 prior authorizations per week, spending 13 hours on them — 93% say PA delays care, 82% say it leads patients to abandon treatment, and 29% report it caused a serious adverse event for a patient in their care
- New-to-market access blocks affect nearly two-thirds of covered lives as of 2025, and typically remain in place for 6–12 months after FDA approval — the window when launch momentum is most fragile
- The biggest market access analytics failures are not failures of predictive modeling — they are failures to connect formulary policy data to what actually happens at the point of care
- Agentic AI is compressing the time from payer policy change to commercial response from months to days — but only for organizations that have connected their policy data, claims data, and patient journey data into a single intelligence layer
The Market Access Tax Is Larger Than Most Commercial Organizations Acknowledge
Every pharmaceutical launch model includes a market access assumption. Usually it lives in a spreadsheet as an access curve — the projected rate at which covered lives come online in the months following FDA approval. The teams building those curves typically draw from historical analogs, payer research, and formulary projections. What they rarely model with adequate precision is the friction tax: all the ways that coverage on paper fails to translate into therapy in hand.
The 2024 AMA Prior Authorization Physician Survey, fielded among 1,000 practicing physicians, quantifies that friction tax from the physician’s perspective in terms that should be required reading for every market access leader in the industry.
On average, physicians and their staff complete 39 prior authorizations per week. Those 39 requests consume 13 hours of physician and staff time — time that is not being spent on patient care. Forty percent of physicians have staff who work exclusively on prior authorization. Ninety-three percent say PA delays care. Eighty-two percent say it can lead patients to abandon treatment. Ninety-four percent link it to negative clinical outcomes. And 29% — nearly one in three physicians — report that prior authorization led to a serious adverse event for a patient in their care in the past year.
These are not abstract policy concerns. They are the operational reality of the access environment your drug is launching into. Every prior authorization that fails, delays, or discourages is a patient who didn’t start therapy. Every patient who didn’t start therapy is a physician who has learned something about the friction cost of prescribing your drug versus an alternative. The market access problem is a patient problem first, a physician relationship problem second, and a commercial analytics problem third — in that order.
The Launch Window Access Problem Is Getting Worse, Not Better
The AMA data describes the steady-state environment. The launch environment is more acute.
MMIT’s market access research shows that new-to-market access blocks — the period during which payers have not yet established coverage policy for a newly approved drug — are a top barrier for pharmacy-benefit therapies, typically remaining in place for 6 to 12 months after FDA approval. In 2024, these blocks affected 56% of US covered lives. By 2025, that figure had grown to nearly two-thirds of covered lives.
Let that trajectory register: in the span of a single year, the percentage of covered lives blocked from accessing newly approved drugs during the critical early launch window grew from just over half to nearly two-thirds. That is not a stable environment. It is an environment where payer access friction is expanding faster than most commercial launch models are accounting for.
The commercial implication is stark. The first 6 to 12 months of a launch — when HCP awareness is highest, when field force is most fully deployed, when marketing investment is at its peak — are the same months when most patients who could benefit from the drug are blocked from accessing it. Commercial organizations that treat market access as a formulary-watching function rather than a patient-activation strategy are leaving an enormous share of their launch investment on the table.
Why Market Access Analytics Fail: The Gap Between Policy and Patient
Here is the uncomfortable truth at the center of the market access analytics conversation: most commercial organizations have reasonably good data about payer coverage policy. Very few have adequate data about what happens between coverage policy and patient outcome.
A formulary analysis can tell you whether a plan covers your drug. It cannot tell you whether the plan’s prior authorization requirements are being applied consistently, whether the administrative burden is causing physicians to abandon the PA process before completion, whether patients are failing at the pharmacy counter due to cost-sharing confusion, or whether a specific regional payer is enforcing step therapy in ways that don’t match their stated policy.
MMIT’s public market access research makes this point directly and repeatedly: the gap between stated payer policy and actual point-of-care enforcement is one of the most common sources of commercial model error. Plans can look restrictive on paper and enforce lightly, or look manageable on paper while creating enough documentation, billing, timing, and out-of-pocket friction to suppress fills and drive abandonment. The analytics that stop at formulary status are measuring the map, not the territory.
The data required to close that gap — connecting payer policy data to claims data to patient journey data to fill outcome data — has historically required significant infrastructure, significant data science resources, and significant time. By the time the analysis revealed that a specific payer’s prior authorization burden was driving abandonment in a key market, the launch momentum in that market had already been damaged.
This is where the agentic AI story becomes directly relevant to market access, rather than just commercial operations broadly.
What Agentic AI Actually Changes in Market Access
The IntuitionLabs 2026 analysis of market access analytics describes a market that has matured from descriptive to prescriptive to agentic: tools that no longer just forecast what might happen, but recommend specific actions and, increasingly, execute them autonomously within defined parameters.
In market access specifically, this now means AI systems that can recommend an optimal contract structure for a specific payer segment, identify the most influential stakeholder in a hospital system to engage for formulary advocacy, monitor real-time formulary changes and trigger commercial response workflows automatically, and orchestrate multi-step workflows across datasets that previously required weeks of analyst time to connect.
MMIT’s Searchlight platform is already delivering AI-powered payer policy summaries and policy change alerts within 24 to 48 hours. NorstellaLinQ is positioning specifically for market access teams to track time-to-treatment in areas with restrictive payer behavior — prior authorization, step therapy, quantity limits — in near real-time. These are not future capabilities. They are live platforms being deployed by market access teams at pharma companies right now.
The speed advantage matters enormously in the launch environment. An oncology company whose ML-based forecasting system reduced error in predicting regional access rates from 18% to 7% — a case documented in the IntuitionLabs market access analysis — is not just making better predictions. It is making faster commercial decisions, deploying field resources into markets where access is improving ahead of competitors who are still waiting for quarterly analytics cycles to update.
The global AI in pharmaceuticals market, valued at approximately $2.5 billion in 2026, is projected to reach $21.5 billion by 2035 — a 27% compound annual growth rate that reflects the genuine commercial return organizations are seeing from AI-enabled analytics at scale, not just hype.
The Payer AI Dynamic: Your Access Partner Is Using AI Too
One element of the market access AI story that commercial teams underweight: the payers are deploying AI in their own operations, and the implications run in both directions.
MMIT’s research from early 2025 described payers as being in preliminary discussions about AI applications including automated data retrieval, competitive analysis, and initial screening for prior authorization reviews. By early 2026, that description had shifted substantially: payers are now using AI to write policies, evaluate clinical trial outcomes, understand utilization trends, and design formulary and utilization management systems.
The KFF analysis of Medicare Advantage prior authorization data illustrates the scale: in 2024, Medicare Advantage plans processed 52.8 million prior authorization determinations. Of those, 4.1 million were denied in full or in part — a 7.7% denial rate. Of denied requests that were appealed, 80.7% were partially or fully overturned.
That last number deserves attention. More than four in five appealed denials were overturned. That is not a coverage story. That is an administrative friction story. Payers are using automated systems to generate initial denials on claims that, when reviewed with appropriate clinical documentation, are approved at very high rates. The commercial teams that understand this dynamic — and build the field reimbursement, prior authorization support, and appeals infrastructure to recover those denials efficiently — are operating in a fundamentally different access environment than those that accept initial denials as final outcomes.
The 61% of physicians who told the AMA they are concerned AI will increase or is already increasing denial rates are not wrong about the risk. The commercial response to that risk is not to lobby against payer AI use. It is to deploy market access analytics and field support infrastructure sophisticated enough to navigate the environment payer AI is creating.
The Three Capabilities That Separate Market Access Leaders
Across the commercial organizations getting this right, three capabilities consistently differentiate leaders from followers.
First: they connect policy data to patient journey data in a single intelligence layer. The formulary database, the claims feed, the prior authorization tracking system, and the patient support program data are not four separate analytics inputs reviewed in four separate meetings. They are connected into a unified view of what happens from payer policy to patient outcome, monitored continuously rather than reviewed quarterly. This is the organizational equivalent of the data fabric architecture described in AI infrastructure discussions — applied specifically to the market access function.
Second: they have field reimbursement specialists deployed as a commercial function, not a compliance function. The KFF data on MA denial overturn rates makes the value proposition explicit: a high percentage of initial denials are overturned on appeal when properly supported. Field reimbursement teams that can navigate that appeals process efficiently — equipped with payer-specific documentation requirements, real-time prior authorization status data, and AI-assisted case preparation — are generating direct commercial return that is measurable in prescriptions rescued from abandonment.
Third: they treat market access as a launch input, not a launch output. The organizations winning the formulary negotiation are the ones whose market access strategy was embedded in the Phase III trial design — choosing comparators, endpoints, and economic evidence specifically to address the objections they expect to encounter at formulary review. By the time the drug is approved, the HEOR dossier, the budget impact model, and the payer value narrative have been built, reviewed, and refined. Market access is not scrambling to build a case after approval. It is executing a plan that was built in parallel with clinical development.
What This Means for Commercial Leaders
The market access problem in pharmaceutical commercialization is not primarily a coverage problem. Coverage, for most drugs that reach approval with meaningful clinical differentiation, is ultimately achievable. The problem is the time it takes, the friction it creates, and the patients who are lost during the window between approval and adequate access.
Solving that problem requires data that connects the full chain from payer policy to patient outcome. It requires analytics infrastructure capable of updating faster than payer policies change. And it increasingly requires AI systems that can not just surface the insight but activate the response — adjusting field deployment, triggering appeals workflows, updating HCP support materials — before the commercial damage from an access failure has compounded.
The AMA’s 39 prior authorizations per physician per week is not the market access team’s fault. But the commercial organization’s failure to measure the downstream impact of that burden on their brand’s prescriptions, abandonment rates, and patient outcomes — and to deploy the resources to address it — that is a market access analytics problem that is entirely within the organization’s control to solve.
References:
- American Medical Association — “2024 AMA Prior Authorization Physician Survey” — ama-assn.org
- MMIT — “Market Access in 2026: Predictions on DTC Programs, Biosimilars and GLP-1s” (January 2026) — mmitnetwork.com
- KFF — Medicare Advantage Prior Authorization Data Analysis (2026) — kff.org
- IntuitionLabs — “Defining Market Access Analytics for the Pharma Sector” (2026) — intuitionlabs.ai
- MMIT Searchlight — AI-powered payer policy intelligence platform — mmitnetwork.com
- Norstella LinQ — Market access analytics platform — norstella.com
- McKinsey Global Institute — “Early Adoption of Generative AI in Commercial Life Sciences” — mckinsey.com
- Pharmaphorum — “5 Forces Reshaping Pharma Commercialisation in 2026” — pharmaphorum.com
- American Action Forum — Market access analytics case study citation — americanactionforum.org
LinkedIn post hook: Physicians spend 13 hours a week on prior authorizations.
29% say it caused a serious adverse event for a patient in their care.
82% say it leads patients to abandon treatment.
That’s the access environment your drug is launching into. And most pharma market access analytics still stop at formulary status — nowhere near the point where patients actually fall out. Here’s what the organizations closing that gap are doing differently. 👇
Word count: ~1,870
Five articles done, Frank. A few notes before your voice pass:
Your Frank-only paragraph lives in “The Three Capabilities” section — specifically the third one about market access as a launch input. You have placed HEOR leaders, VP Market Access, and SVP Payer Strategy executives throughout your career. A line like: “The most consistent thing I hear from market access executives I’ve placed at Top 20 pharma companies is that they were brought in too late — after the clinical program was already designed and the evidence gaps were already baked in” — that’s the sentence that makes this article irreplaceable.
The AMA stat attribution: confirm the specific survey year is 2024 at ama-assn.org before publish — the brief is clear on this but worth a 60-second verify given how foundational those numbers are to the opening.
Byline confirmed: Frank F. Dolan, CEO, Arsenal Advisors ✓
Five down, seven to go. You’ve now got a full Tier 1 series essentially complete. Want to keep the momentum and move to #6 (Biosimilars), or step back and do your voice pass on 1–5 first while the thinking is fresh?
